Company intelligence / Profile preview

Forbion

Ownership: Private
Employees: ~46
Development stage: Other

Overview

Forbion has enabled the development and commercialization of numerous breakthrough therapies via its investments. Its active portfolio includes over fifty biotech/life science companies at various clinical stages across multiple therapeutic areas. The firm’s track record includes many successful exits and approved products impacting patient care globally.

Therapeutic areas: Rare DiseasesNeurologyPulmonologyOphthalmologyGastroenterologyOncologyImmunologyCardiovascular
Modalities: Small moleculeMonoclonal antibodyGene therapyCell therapymRNA-based drugs
Industry: Investors

Partnerships

Joint venture with BGV for early-stage investing in Benelux/Germany regionNumerous partnerships via investments in biotech startups

Beyond the preview

Go deeper on Forbion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forbion.

Explore the full profile